Sunrise Pharmaceuticals
Private Company
Funding information not available
Overview
Sunrise Pharmaceuticals is a private, commercial-stage generics company with a fully integrated model from development to market. Following a strategic refocus on Abbreviated New Drug Applications (ANDAs) in 2012, the company achieved its first ANDA approval in 2014 and now markets products under its own label. It targets the entire US generic drug supply chain, including retailers, wholesalers, distributors, health systems, and government entities, with a stated aim of expanding its robust product pipeline to provide affordable medications.
Technology Platform
Integrated generic drug development and manufacturing platform focused on bioequivalence studies, analytical development, formulation, and regulatory filing of Abbreviated New Drug Applications (ANDAs).
Opportunities
Risk Factors
Competitive Landscape
Sunrise competes in the highly fragmented and competitive US generic pharmaceutical market against large global players (e.g., Teva, Sandoz, Viatris) and numerous agile private companies. Competition is primarily on price, product portfolio breadth, reliability of supply, and speed to market for new generics.